Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...

Selma Blair recounted a date from the past with Robbie Williams during an appearance on The Drew Barrymore Show. She ...

Selma Blair discussed her heartbreaking MS relapse during a candid chat on Tuesday's Drew Barrymore Show. The actress, 52, who was diagnosed with multiple sclerosis in 2018, said during a past relapse ...

Cladribine (Mavenclad) is a pill that you take for a total of 16 or 20 days over the course of 2 years. You’ll have treatment for 2 weeks per year, with each session lasting 4 or 5 days.

Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Mavenclad is a tablet formulation of cladribine that’s approved for adults with relapsing forms of MS. The… Cognitive rehabilitation scientist Yael Goverover, PhD, has been recognized with the ...

The second deal is with German pharma company Merck for its multiple sclerosis drug Mavenclad (cladribine), and involves a new outcomes-based pricing agreement. Simon Stevens hailed the Merck ...